Carl Michael Gay

This study shows DLL3 expression level predicts response and long-term survival in SCLC patients treated with tarlatamab.

This study identifies YAP1-positive cells in relapsed SCLC that exhibit drug tolerance and transition from SCLC to LCNEC-like features, losing some targets but gaining others.

This study uses CyTOF to profile circulating tumor cells in SCLC patients, identifying subtype-specific markers and treatment response correlations.

This study identifies three distinct DDR phenotypes in SCLC associated with chemotherapy response and tumor evolution.

This study examines genomic and TCR repertoire heterogeneity in SCLC, finding that lower TCR heterogeneity and mutational burden correlate with better survival.